adenovirus
adv
nonenvelop
doublestrand
dna
virus
caus
upper
lower
respiratori
tract
infect
either
sporad
fashion
epidem
current
distinct
adv
serotyp
isol
human
adv
typic
caus
mild
selflimit
respiratori
infect
although
adv
caus
varieti
clinic
manifest
immunocompromis
patient
adenoviru
infect
often
lead
fatal
outcom
exampl
immunodefici
state
solid
organ
stem
cell
transplant
sever
adenoviru
infect
may
occur
mortal
outbreak
adenovir
pneumonia
occasion
report
young
adult
women
militari
personnel
respiratori
tract
infect
lead
caus
hospit
militari
traine
medic
field
studi
us
militari
show
recruit
boot
camp
infect
adv
patient
pneumonia
infect
adenoviru
studi
south
korean
militari
report
preval
adv
among
militari
recruit
acut
respiratori
symptom
upper
respiratori
tract
infect
caus
adv
may
also
progress
pneumonia
recent
sever
case
seri
report
describ
recruit
die
boot
camp
due
sever
adenovir
pneumonia
south
korea
sinc
even
mortal
result
clinic
outcom
adv
infect
could
affect
select
bia
report
adv
infect
may
sever
higher
incid
progress
respiratori
multiorgan
failur
compar
viral
etiolog
except
influenza
thu
clinic
data
report
regard
predict
factor
respiratori
failur
associ
adv
infect
adv
infect
diagnos
earli
increas
monitor
earli
appli
organ
support
may
improv
clinic
outcom
patient
howev
suffici
data
distinct
characterist
adv
infect
immunocompet
patient
current
unavail
previous
observ
adenovirusposit
communityacquir
pneumonia
cap
patient
high
fever
respond
differ
antipyret
treatment
compar
cap
patient
test
posit
virus
bacteria
therefor
primari
goal
studi
compar
clinic
characterist
adv
nonadvposit
cap
patient
among
immunocompet
militari
personnel
identifi
distinct
characterist
studi
singlecent
retrospect
cohort
studi
review
medic
record
patient
admit
arm
forc
chuncheon
hospit
gangwon
provinc
south
korea
referr
hospit
gangwon
provinc
cap
treatment
januari
decemb
base
uniqu
characterist
korean
militari
medic
system
militari
personnel
treat
initi
militari
hospit
despit
lack
diagnost
modal
ethic
approv
obtain
institut
review
board
arm
forc
medic
command
waiv
need
inform
consent
retrospect
observ
natur
studi
patient
includ
studi
admit
cap
treatment
viral
polymeras
chain
reaction
pcr
test
perform
upper
respiratori
specimen
exclus
criteria
follow
respiratori
viral
pcr
test
perform
incomplet
record
immedi
transfer
tertiari
hospit
advanc
care
primari
reason
admiss
manag
comorbid
diseas
cap
defin
use
definit
set
forth
infecti
societi
americaamerican
thorac
societi
consensu
guidelin
short
cap
diagnos
patient
symptom
associ
respiratori
tract
infect
newonset
lung
infiltr
pleural
effus
chest
xray
chest
comput
tomographi
scan
defin
fever
temperatur
greater
equal
record
tympan
rout
bodi
temperatur
patient
check
everi
hour
admiss
day
day
admiss
bodi
temperatur
often
measur
within
h
patient
febril
sens
worsen
sign
inflamm
also
record
bodi
temperatur
begin
antipyret
administr
standard
antipyret
treatment
protocol
fever
control
studi
antipyret
therapi
administ
upon
reach
bodi
temperatur
interv
antipyret
administr
accord
pharmacodynam
although
perform
addit
antipyret
treatment
patient
fever
two
consecut
measur
deterior
clinic
symptom
includ
myalgia
gener
weak
cough
nasal
congest
dyspnea
within
h
antipyret
administr
respons
antipyret
treatment
classifi
follow
complet
respons
record
bodi
temperatur
drop
observ
antipyret
treatment
sustain
throughout
partial
respons
record
bodi
temperatur
drop
observ
resurg
observ
need
addit
antipyret
respons
record
sustain
bodi
temperatur
equal
observ
antipyret
use
unrespons
initi
antibiot
treatment
defin
observ
deterior
evidenc
worsen
clinic
symptom
sign
andor
progress
lesion
radiolog
studi
h
initi
antibiot
treatment
data
includ
age
sex
smoke
histori
comorbid
condit
symptom
clinic
sign
initi
laboratori
radiolog
find
cultur
result
pneumonia
sever
index
clinic
cours
length
hospit
stay
surviv
outcom
collect
electron
medic
record
evalu
etiolog
sputum
nasopharyng
oropharyng
secret
blood
urin
use
microbiolog
cultur
approach
respiratori
specimen
typic
obtain
selfextract
sputum
sputum
specimen
could
obtain
upper
respiratori
tract
specimen
oropharyng
nasopharyng
swab
use
viral
pcr
test
multiplex
realtim
pcr
perform
use
realq
rv
detect
kit
biosewoom
seoul
korea
roch
light
cycler
ii
instrument
roch
diagnost
mannheim
germani
respiratori
virus
includ
test
follow
adenoviru
rhinoviru
influenza
viru
ab
respiratori
syncyti
viru
ab
metapneumoviru
bocaviru
coronaviru
parainfluenza
viru
patient
given
chest
xray
andor
high
resolut
comput
tomographi
hrct
time
emerg
depart
visit
initi
antibiot
agent
intraven
administ
patient
initi
antibiot
regimen
follow
adher
treatment
guidelin
communityacquir
pneumonia
korea
evidencebas
approach
appropri
antimicrobi
therapi
korean
academi
tuberculosi
respiratori
diseas
antipyret
agent
regimen
use
studi
follow
propacetamol
intraven
administ
dose
g
need
maximum
g
per
day
acetaminophen
given
oral
dose
tablet
mg
per
tablet
everi
h
maximum
tablet
per
day
physic
cool
method
appli
febril
patient
includ
extern
air
ice
bag
water
blanket
techniqu
data
present
mean
standard
deviat
median
interquartil
rang
continu
variabl
number
percentag
categor
variabl
data
analyz
use
kolmogorovsmirnov
test
normal
distribut
data
compar
use
mannwhitney
utest
student
ttest
continu
variabl
fisher
exact
test
categor
variabl
statist
analys
perform
use
spss
version
spss
inc
chicago
il
usa
twosid
pvalu
consid
indic
signific
studi
period
cap
patient
admit
arm
forc
chuncheon
hospit
fig
patient
admit
via
emerg
depart
case
case
exclud
reason
exclus
respiratori
viral
pcr
test
patient
incomplet
data
patient
immedi
transfer
tertiari
medic
center
two
patient
admiss
treatment
underli
diseas
two
patient
two
patient
admit
suspici
combin
underli
diseas
manag
acut
asthma
exacerb
consequ
patient
enrol
studi
among
patient
posit
pcr
test
adenoviru
adv
group
patient
neg
pcr
test
adenoviru
nonadv
group
among
nonadv
group
patient
pathogen
detect
patient
cultur
assay
unknown
pathogen
group
patient
diagnos
virus
bacteria
combin
pathogen
nonadv
group
tabl
show
baselin
characterist
patient
adv
nonadv
group
admiss
median
age
year
patient
healthi
male
prior
onset
ill
number
current
smoker
significantli
higher
adv
group
nonadv
group
vs
respect
recent
smoker
day
identifi
adv
group
n
patient
underli
diseas
asthma
n
allerg
rhiniti
n
pneumothorax
n
differ
durat
symptom
time
symptom
onset
admiss
observ
two
group
vs
p
patient
clinic
symptom
sign
upper
lower
respiratori
tract
infect
adv
group
patient
show
symptomat
instabl
fever
cough
myalgia
headach
nasal
congest
admiss
initi
vital
sign
pneumonia
sever
index
psi
score
significantli
differ
two
group
compar
laboratori
radiolog
find
adv
nonadv
group
tabl
percentag
patient
leukopenia
thrombocytopenia
higher
adv
patient
p
leukocytosi
common
nonadv
group
patient
p
level
infect
marker
creactiv
protein
crp
procalcitonin
show
differ
two
group
addit
total
bilirubin
creatinin
level
show
signific
differ
two
group
possibl
caus
agent
identifi
adv
group
patient
nonadv
group
patient
instanc
adv
group
patient
coinfect
virus
rhinoviru
n
influenza
viru
n
respiratori
syncyti
viru
n
parainfluenza
viru
n
bacteria
combin
etiolog
common
nonadv
group
patient
rhinoviru
commonli
identifi
pathogen
nonadv
group
patient
common
bacteri
pathogen
streptococcu
pneumonia
adv
group
patient
haemophilu
influenza
nonadv
group
patient
common
radiolog
featur
groundglass
opac
consolid
adv
group
consolid
nonadv
group
p
unilater
distribut
domin
group
vs
howev
multilobar
lobe
involv
common
nonadv
group
vs
p
presenc
pleural
effus
significantli
differ
two
group
figur
show
chang
mean
bodi
temperatur
admiss
day
admiss
adv
nonadv
group
patient
addit
also
compar
fever
respons
antipyret
treatment
patient
pathogen
group
adv
nonadv
group
result
shown
tabl
gener
adv
group
patient
much
longer
durat
fever
admiss
nonadv
patient
day
vs
day
day
p
symptom
onset
day
vs
day
day
p
evalu
degre
fever
assess
mean
temperatur
number
patient
maxim
temperatur
admiss
adv
group
patient
higher
mean
temperatur
admiss
vs
vs
p
observ
instanc
temperatur
p
adv
group
patient
took
longer
attain
maxim
fall
bodi
temperatur
nonadv
unknown
pathogen
group
patient
admiss
vs
vs
p
approxim
adv
group
patient
respons
antipyret
treatment
repres
higher
proport
compar
observ
nonadv
unknown
pathogen
group
patient
p
howev
proport
complet
respons
antipyret
treatment
compar
lower
patient
adv
group
observ
nonadv
unknown
pathogen
group
physician
suspect
patient
atyp
pathogen
persist
deterior
symptom
sign
despit
treatment
appropri
empir
antibiot
day
thu
compar
clinicolaboratori
find
adv
nonadv
group
patient
unrespons
initi
antibiot
treatment
tabl
number
patient
respons
initi
antibiot
treatment
adv
nonadv
group
respect
percentag
patient
leukocytosi
monocytopenia
higher
adv
patient
although
signific
differ
white
blood
cell
platelet
count
two
group
leukopenia
thrombocytopenia
show
signific
differ
studi
patient
show
differ
patient
unrespons
initi
antibiot
treatment
p
p
respect
greater
number
adv
group
patient
exhibit
respons
antipyret
treatment
compar
nonadv
group
patient
vs
p
well
number
patient
reach
p
addit
adv
group
patient
higher
mean
temperatur
admiss
nonadv
group
patient
vs
p
tabl
compar
clinicolaboratori
variabl
combin
adv
cadv
nonadv
adv
identifi
pathogen
oaip
group
patient
compar
cadv
nonadv
patient
patient
oaip
group
exhibit
follow
characterist
current
smoke
leukopenia
lymphopenia
monocytopenia
thrombocytopenia
exhibit
longer
durat
fever
symptom
onset
higher
maxim
temperatur
admiss
exhibit
respons
antipyret
admiss
patient
receiv
empir
antibiot
treatment
tabl
follow
gener
cephalosporin
plu
azithromycin
common
regimen
n
follow
piperacillintazobactam
plu
respiratori
quinolon
n
chang
antibiot
treatment
regimen
frequent
adv
group
patient
nonadv
patient
vs
p
durat
antibiot
treatment
significantli
differ
two
group
studi
evalu
administr
cidofovir
adjuv
intraven
immunoglobulin
ivig
addit
patient
receiv
mechan
ventil
extracorpor
membran
oxygen
support
admiss
mean
dose
antipyret
administ
higher
adv
group
patient
nonadv
group
patient
vs
g
p
although
overal
durat
antipyret
significantli
differ
two
group
studi
identifi
advers
event
antipyret
administr
hypotens
gastrointestin
troubl
skin
rash
elev
liver
enzym
commonli
observ
adv
group
patient
p
time
overal
clinic
stabil
admiss
significantli
longer
adv
group
patient
nonadv
group
patient
vs
p
addit
length
hospit
significantli
differ
two
group
patient
die
studi
studi
describ
clinic
characterist
advposit
communityacquir
pneumonia
immunocompet
adult
patient
import
find
adv
group
patient
longer
durat
fever
symptom
onset
admiss
higher
mean
bodi
temperatur
admiss
higher
number
patient
bodi
temperatur
admiss
longer
durat
maxim
fall
bodi
temperatur
admiss
higher
rate
respons
antipyret
treatment
admiss
compar
nonadv
group
patient
addit
instanc
leukopenia
thrombocytopenia
greater
adv
group
patient
nonadv
group
patient
although
patient
unrespons
initi
antibiot
treatment
differ
two
group
epidemiolog
studi
adv
south
korea
militari
traine
personnel
perform
yoo
et
al
report
adenoviru
identifi
specimen
febril
respiratori
ill
fri
pneumonia
patient
studi
review
militari
patient
fri
pneumonia
test
respiratori
virus
octob
may
proport
patient
pneumonia
hospit
rate
differ
without
adenoviru
infect
howev
adenovirusinfect
patient
significantli
higher
risk
requir
intens
care
mechan
ventil
support
notabl
find
indic
adenoviru
infect
occasion
associ
mortal
morbid
loss
combat
strength
increas
cost
care
date
littl
data
report
characterist
fever
adv
infect
especi
immunocompet
patient
studi
compar
characterist
fever
adv
nonadv
group
patient
adv
group
patient
longer
durat
fever
higher
proport
peak
bodi
temperatur
patient
infect
variou
viral
respiratori
pathogen
unknown
pathogen
similarli
ho
et
al
observ
viral
monopathogen
patient
higher
mean
bodi
temperatur
bacteri
monopathogen
patient
addit
dualpathogen
patient
pneumonia
either
influenza
b
higher
mean
bodi
temperatur
although
significantli
differ
respect
monopathogen
howev
still
lack
detail
data
specif
pathogenrel
clinic
characterist
especi
fever
immunocompet
patient
thu
data
like
aid
physician
determin
diagnost
therapeut
consider
time
admiss
also
evalu
respons
antipyret
treatment
adv
nonadv
group
data
show
adv
group
patient
exhibit
higher
proport
individu
respons
antipyret
treatment
compar
nonadv
unknown
pathogen
group
patient
weiss
et
al
evalu
effect
acetaminophen
fever
bacteri
vs
viral
infect
children
conclud
correl
fever
respons
acetaminophen
etiolog
fever
reveal
use
respons
antipyret
treatment
predict
etiolog
pneumonia
howev
data
suggest
may
differ
antipyret
respons
adv
compar
etiolog
first
data
report
immunocompet
adult
studi
sever
limit
first
studi
retrospect
design
singlecent
confound
variabl
antibiot
regimen
inconsist
time
antipyret
administr
may
possibl
affect
clinic
cours
fever
respons
antipyret
treatment
second
studi
reflect
unmeasur
variabl
genotyp
adenoviru
differ
sever
ill
adv
nonadv
group
may
led
differ
characterist
fever
respons
antipyret
third
conduct
studi
militari
hospit
cohort
repres
gener
popul
sinc
militari
environ
differ
characterist
live
environ
nutritionimmun
statu
mode
pathogen
spread
fourth
select
bia
patient
admit
cap
could
respiratori
pcr
test
perform
examin
limit
upper
respiratori
tract
adv
serotyp
viral
burden
analys
perform
fifth
sever
potenti
relev
pathogen
identifi
studi
patient
thu
uncertain
whether
adenoviru
lead
pathogen
patient
multipl
pathogen
includ
adenoviru
addit
uncertain
whether
patient
unknown
pathogen
infect
pathogen
best
knowledg
first
studi
analyz
characterist
fever
respons
antipyret
therapi
immunocompet
adult
patient
adenovirusinfect
cap
patient
adv
group
clinic
characterist
significantli
differ
nonadv
group
includ
longer
durat
fever
high
fever
higher
proport
respons
antipyret
treatment
admiss
